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James Cantley and Frances M. Ashcroft*What is type 2 diabetes?
Diabetes mellitus is a term that covers a multitude of
problems with many etiologies, unified by one common
feature: the pathological elevation of blood glucose. Sus-
tained hyperglycemia leads to tissue damage in susceptible
organs and eventually results in secondary complications
including retinopathy, nephropathy, peripheral neuropathy,
cardiovascular disease and stroke [1-3]. Diabetes currently
affects 387 million people worldwide, and this number
is predicted to increase to 592 million by 2035 [4]. The
dramatic rise in the disease in recent years not only
causes individual misery, but also places an enormous
and increasing burden on healthcare systems and the
global economy [5,6]. Indeed, many countries spend as
much as 10 % of their healthcare budget on treating dia-
betes and its complications.
Type 2 diabetes (T2D) is the most common form of the
disease, accounting for approximately 90 % of cases [6]. It
has a strong genetic component that is amplified by fac-
tors such as age, obesity, diet, physical activity and preg-
nancy. T2D is characterized by insufficient secretion of
insulin from the β-cells of the pancreatic islets, coupled
with impaired insulin action in target tissues such as
muscle, liver and fat (a condition termed insulin resist-
ance). Hyperglycemia results when insulin secretion is
unable to compensate for insulin resistance [7]. Insulin
resistance is increased during obesity, which explains, at
least in part, why T2D risk is enhanced by obesity. The
regulation of glucose homeostasis by insulin is summa-
rized in Fig. 1.
Type 1 diabetes (T1D) is much less common than T2D,
accounting for <10 % of cases. It is precipitated by an
autoimmune attack on the β-cells that results in an insulin
deficient state, although a small number of functioning
β-cells may remain [8]. Typically, T1D presents in child-
hood or young adulthood.* Correspondence: frances.ashcroft@dpag.ox.ac.uk
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article, unless otherwise stated.In addition, there are rare inherited monogenic forms
of diabetes that usually present in early life, and account
for only 1 to 2 % of all diabetes cases. Unlike T2D, where
it is believed multiple genes predispose to the disease,
monogenic diabetes is caused by mutations in a single
gene. Many of these genes encode transcriptional regula-
tors, metabolic enzymes and ion channels that regulate
β-cell stimulus-secretion coupling, or they may affect
the development of the pancreas. Interestingly, common
genetic variants in many of the genes known to cause
monogenic diabetes enhance T2D risk; thus, their study
may help elucidate the etiology of T2D.
T1D must be treated by insulin injections, due to the
lack of β-cells. Therapy for T2D consists initially of diet-
ary control and lifestyle modifications, followed by oral
hypoglycemic agents, which may increase insulin secretion
(for example, sulfonylureas) or reduce insulin resistance
or hepatic glucose output (for example, metformin). If
these fail to control hyperglycemia, then insulin is given.
Monogenic diabetes is treated in different ways according
to the gene involved.Why are there no other hormones that can
substitute for insulin?
Most control systems, including physiological ones, have
built-in redundancy, which ensures that when one sys-
tem fails another takes over. For example, several hor-
mones can elevate blood glucose. However, only insulin
can reduce blood glucose. At first this might seem sur-
prising, but it is worth remembering that too much insu-
lin has far more immediate and devastating effects than
too little insulin. If blood glucose falls below 2 mmol/l
for as little as 5 minutes, it can cause lethal brain damage.
By contrast, it is only when blood glucose is chronically el-
evated over many weeks and months, due to a sustained
lack of insulin, that the complications of diabetes are pro-
duced. Thus, insulin is a ‘Goldilocks’ hormone in that both
too much and too little are dangerous. But although lack
of insulin, and the consequent diabetes, receives much at-
tention, an acute excess of insulin is far more damaging.Central. This is an Open Access article distributed under the terms of the
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Fig. 1. Glucose homeostasis. A rise in blood glucose triggers insulin
secretion from β-cells (blue) within the pancreatic islets. Insulin lowers
blood glucose by acting on target tissues, suppressing glucose output
from the liver and stimulating glucose uptake into muscle and fat.
α-cells (yellow) are the glucagon-secreting cells of the pancreas;
δ-cells (green) secrete somatostatin
Cantley and Ashcroft BMC Biology  (2015) 13:33 Page 2 of 7Insulin’s other function - its ability to enhance growth -
is mirrored by several hormones, such as insulin-like
growth factor 1 and 2. It is only the role of insulin in glu-
cose homeostasis that is unique. We therefore speculate
that the danger of hypoglycemia is the reason for the
unique ability of insulin, acting via a single receptor, to
lower blood glucose. In our evolutionary history, when
humans battled with inadequate food and unplanned exer-
cise (escaping predators) hypoglycemia was more likely
than hyperglycemia. In this situation, a single means of
lowering blood glucose is advantageous as there is less
chance of inadvertent hypoglycemia. By contrast, the pres-
ence of numerous feedback systems to bolster blood sugar
is beneficial. Although T2D is an increasing problem in
societies today, in evolutionary terms it is of little signifi-
cance because it generally presents after an individual’s
reproductive age. Furthermore, it is only in very recent
times that we have been exposed to the plentiful availabil-
ity of high calorie diets and sedentary lifestyles that drive
obesity and T2D.
How do β-cells avoid inappropriate insulin
secretion?
β-cells have evolved important metabolic features to
avoid excessive insulin secretion and hypoglycemia, par-
ticularly during exercise. First, insulin secretion is ex-
quisitely sensitive to changes in blood glucose. This is
achieved by coupling glucose metabolism with insulin
secretion via changes in intracellular ATP levels, β-cell
electrical activity and insulin vesicle release. When blood
glucose rises, most of the glucose taken up by the β-cell
is metabolized via oxidative phosphorylation, thereby
elevating intracellular ATP. This closes KATP channels,
so triggering β-cell electrical activity and an influx of
calcium (via voltage-gated calcium channels) that, in turn,
stimulates insulin release (Fig. 2). Conversely, when bloodglucose levels fall, insulin secretion is rapidly switched off
due to a reduction in intracellular ATP in β-cells, leading
to opening of KATP channels, membrane hyperpolariza-
tion, reduced calcium entry and thereby inhibition of insu-
lin secretion (Fig. 2).
Second, a number of metabolic genes that are widely
expressed in other tissues are not expressed in pancreatic
β-cells [9-11]. Such ‘disallowed’ genes include those encod-
ing lactate dehydrogenase (LDHA) and the monocarboxyl-
ate transporter 1 (MCT1/SLC16A1), which are involved in
the metabolism of lactate and pyruvate. This prevents insu-
lin secretion in response to circulating lactate and pyruvate
during exercise. Mutations in the SLC16A1 gene that result
in its aberrant expression in β-cells provoke exercise-
induced hypoglycemia by enabling pyruvate-induced
insulin secretion [12,13]. In early humans, exercise-
induced hypoglycemia could be lethal as it would im-
pede escape from a predator; the absence of MCT1
ensures insulin secretion remains switched off during
exercise. Similarly, adrenaline inhibits insulin secretion,
ensuring blood glucose levels do not drop during exer-
cise or the ‘fight-or-flight’ response.
What causes the insulin deficiency in type 2
diabetes?
The impaired insulin secretion found in T2D could be
due to a decline in the cellular secretory rate (that is, in
individual β-cell function), or to a decrease in β-cell
mass (the product of β-cell size and number), or both.
While there has been much debate about the relative
contributions of secretory dysfunction and loss of β-cell
mass to impaired insulin secretion in T2D, a consensus
view is still lacking. This may, in part, be due to the diffi-
culty in obtaining human islets (especially from T2D
donors) of sufficient quality and quantity for functional
studies, as islet isolation programs primarily operate to
provide islets from healthy donors for transplantation
therapy [14]. Furthermore, there are several factors that
may vary between human islet preparations, thereby
confounding the comparison of control and T2D islet
function: donors may have been maintained on different
cocktails of drugs prior to death, genetic background
and environmental factors may be poorly controlled, and
variations in the cold ischemic time to which the islets
are exposed during pancreas transport and islet isolation
may alter islet gene expression and function [15]. How-
ever, when many of the above variables are controlled
for, studies with modest sample sizes (n = 5 to 17 cases)
have clearly shown that glucose-stimulated insulin secre-
tion (GSIS) is defective in islets from T2D donors, relative
to non-diabetic donors [16-18]. In two of these studies, is-
lets from T2D donors responded normally to non-glucose
stimuli, suggesting defective GSIS in these cohorts is







































Fig. 2. Glucose-stimulated insulin secretion. At basal levels of blood glucose (left-hand panel), the ATP-sensitive K+ channels (KATP channels) in
pancreatic β-cells remain open, maintaining membrane hyperpolarization, Ca2+ channel closure and inhibiting insulin secretion. A rise in blood
glucose (right-hand panel) drives oxidative phosphorylation and ATP production, resulting in the closure of KATP channels, plasma membrane
depolarization, calcium influx and insulin vesicle exocytosis
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tutive defect in insulin exocytosis [16,18]. Nevertheless,
more work is needed, both to increase the numbers of
cases studied and to investigate the nature of the defective
GSIS response in detail.
Histological studies of β-cell mass are more straight-
forward because they can be conducted on fixed tissues.
Several studies have reported a decrease in β-cell mass
in T2D [19-21]. However, an important caveat with these
experiments is that β-cells are usually identified by insulin
staining. This means that the insulin content must be high
enough for it to be detected histologically - β-cells with
greatly reduced insulin content will not be counted and
β-cell mass thus underestimated. Recent studies indicate
that T2D islets contain many β-cells that can be identified
as such using electron microscopy by their characteristic
‘poached-egg’ insulin granules, but where the granules
are strikingly few and insulin is undetectable by immu-
nostaining [17]. Hyperglycemia produces similar effects
in a mouse model of diabetes [22]. Thus, the extent to
which β-cell mass is reduced in T2D remains unclear.
While there is good evidence that islet insulin staining
(aka content) decreases with time, the relative contribu-
tions of decreased insulin content, fewer β-cells and im-
paired stimulus-secretion coupling to reduced insulin
secretion in T2D is still uncertain. Notwithstanding this,
in the 5 year period following diagnosis, patients with
T2D show a 25 % reduction in the mass of insulin-
positive cells, relative to non-diabetic controls, whereas
in individuals with longstanding T2D (>15 years), β-cell
mass is reduced by over 50 % [21]. This progressive loss
of β-cell mass during disease progression places anever-greater secretory burden on the β-cells that remain
functional. Their resilience is likely determined by a
complex interplay between environmental, genetic and
epigenetic factors.
Do changes in β-cell identity contribute to type 2
diabetes?
It is clear that multiple mechanisms are involved in the
development of T2D. However, recent evidence sug-
gests that β-cell identity may not be fixed, and changes
in β-cell identity may contribute to defective insulin se-
cretion in T2D.
It is well established that hyperglycemia in mice results
in altered expression of β-cell transcription factors and
defective insulin secretion, a situation described as β-cell
dedifferentiation [23]. Recent elegant studies have shown
that deletion of certain transcription factors in mice,
such as FOXO1 [24], leads to dedifferentiation of pan-
creatic β-cells, which lose their insulin content and re-
vert to islet progenitor-like cells. Similarly, expression of
the progenitor cell marker Ngn3 has been reported in a
mouse model of diabetes [25]. Whether this is the case
for human β-cells in T2D is as yet unclear [23]. How-
ever, marked changes in β-cell transcription factors are
observed in humans with T2D [26] and in non-human
primates with diet-induced pre-diabetes [27].
It is well established that the loss of insulin immuno-
staining seen in many mouse models of diabetes is paral-
leled by an increase in glucagon immunostaining. These
changes appear to be driven by hyperglycemia. In one of
these mouse models, lineage tracing revealed that a small
number of β-cells start to express glucagon [22]. However,
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or if they represent an intermediate cell type that ex-
presses glucagon as well as many β-cell proteins (except
for insulin). In contrast, lineage tracing has also shown
that both α-cells [28] and δ-cells [29] can convert to
fully functioning β-cells, highlighting the potential plas-
ticity of islet cells.
Thus, much of the current research in this area is
focused on how to differentiate β-cells from progenitor
cells or other islet cell types. Interestingly, the effects of
hyperglycemia on β-cell dedifferentiation, loss of insulin
content and glucagon expression can be reversed by
tight control of blood glucose [22,25].
Is obesity a driver of β-cell failure?
The current global epidemics of obesity and T2D show
remarkably similar trends and geographic distribution,
and there is good evidence that the risk of T2D is in-
creased by obesity [30]. However, obesity appears to
exert its effect primarily on insulin resistance rather than
on β-cell function, and only a minority of obese individ-
uals will develop T2D [31], while many non-obese individ-
uals will do so [32]. Furthermore, obesity is associated
with an enhanced insulin response to glucose in non-
diabetic individuals [33,34], and recent histological studies
have revealed obesity is associated with a 50 % increase in
β-cell mass [35]. Thus, it appears that far from obesity
causing β-cell failure, the inherent ability for β-cell func-
tion to adapt to obesity fails in some individuals, resulting
in T2D [31].
To what extent is type 2 diabetes a genetic
disease?
An individual’s risk of developing T2D is determined by
a complex interplay between genetic and environmental/
lifestyle factors. Genotype clearly plays an important
role: prospective studies of monozygotic twins have
shown a 76 % concordance rate for T2D, and a 96 %
concordance rate for impaired glucose tolerance [36].
Furthermore, a family history of T2D more than doubles
an individual’s risk of developing the disease [37]. But at
the same time the epidemiological evidence shows a dra-
matic rise in T2D rates over the past 60 years that
clearly cannot be due to genetic change, but is associated
with alterations in diet and behavior, including a more
sedentary lifestyle and increased consumption of calorie-
dense foods [6].
T2D risk may also be influenced by epigenetic changes,
which are heritable alterations affecting cell function which
do not involve changes in the DNA sequence. These are
largely determined by environmental factors, such as par-
ental nutrition. Recent evidence suggests that β-cells from
T2D patients show altered DNA methylation (a common
epigenetic mark) with changes in gene expression profiles[38]. Rodent studies have shown that suboptimal maternal
or paternal nutrition can influence chromatin modifica-
tions and gene expression in β-cells of subsequent off-
spring, consistent with epigenetic transmission [39,40]. In
humans maternal and early-life nutrition is known to influ-
ence the risk of T2D in offspring [41,42]. Further studies
will be needed to clarify the emerging role of epigenetics in
the etiology of T2D.
Are specific gene variants associated with type 2
diabetes?
This is not a straightforward question to answer.
T2D is a polygenic disease, and current evidence favors
the idea that in most individuals, the risk of developing
the disease is determined by the combination of at-risk
variants at many gene loci, each of which alone confers
only a small increase in disease risk [43]. This makes T2D
distinct from the much rarer monogenic forms of diabetes,
such as maturity onset diabetes of the young (MODY) and
neonatal diabetes [44]. It also indicates that T2D is not a
single entity, as hyperglycemia may be produced by differ-
ent combinations of genes in different individuals, which
may also result in phenotypic variations.
Currently, the best method for identifying genes con-
tributing to polygenic diseases are genome-wide associ-
ation studies (GWAS). These are based on the association
of common genetic variants - single-nucleotide polymor-
phisms - with a given phenotype, such as hyperglycemia.
To date, more than 70 gene loci have been found to be as-
sociated with T2D in large-cohort studies [45], with the
majority of these loci being implicated in β-cell function.
One problem with GWAS studies is the size of the co-
horts that must be studied (sometimes >100,000 people)
to generate sufficient statistical power. Such large cohorts
are difficult to phenotype in sufficient depth to reveal the
complex physiology underlying T2D. Thus, most studies
inevitably rely on relatively simple phenotyping procedures,
such as measurement of fasting blood glucose, which do
not adequately reveal the underlying etiology. Therefore,
efforts to improve disease phenotyping are important. A
recent study analyzed the association of 37 hyperglycemia
susceptibility loci with three key traits that influence blood
glucose: insulin sensitivity, β-cell insulin processing and
insulin secretion [46]. This revealed that risk loci were
clustered into three distinct groups, each associated
with only one of the three phenotypic measurements.
This study highlights both the marked physiological het-
erogeneity underlying glycemic traits, and the need for
stratification of diabetes phenotypes to enhance the
power of GWAS.
New approaches to studying genotype-phenotype in-
teractions in β-cells are urgently needed. Some progress
towards this goal was made in a recent study, which an-
alyzed islets isolated from human donors with differing
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direct influence of a subset of diabetes risk loci on im-
paired insulin secretion ex vivo [18], and provided mech-
anistic insights into the role of these genetic variants.
Is a personalized treatment for type 2 diabetes,
based on genotype, possible?
In some diseases, such as breast cancer, genotyping is
routinely used to predict whether a patient will benefit
from a particular drug [47]. Genotyping has also revolu-
tionized therapy in some types of monogenic diabetes
[48]. The potential for genotype-specific therapy in T2D
is less clear, principally because each gene variant only ex-
plains a small degree of disease risk. However, a recent
study revealed that in T2D patients carrying an alpha-2A-
adrenergic receptor mutation, treatment with a drug tar-
geted to this receptor restored insulin secretion [49]. This
raises the tantalizing possibility of mining GWAS data for
new drug targets to develop personalized treatments for
groups of individuals with specific subtypes of T2D.
Are other islet cell types involved in the
pathogenesis of type 2 diabetes?
It is now well established that T2D is not caused simply
by lack of insulin and that impaired glucagon secretion
from pancreatic α-cells also plays a pivotal role. Gluca-
gon elevates blood glucose by stimulating gluconeogen-
esis and glucose output from liver hepatocytes. In T2D
there is a marked increase in glucagon secretion at high
glucose, which exacerbates the hyperglycemic effects of
insulinopenia [50]. There is also too little glucagon
secretion at low glucose, which may precipitate fatal
hypoglycemia [50].
Glucagon, a long-neglected player in glucose homeosta-
sis and T2D, has recently taken center stage. The spec-
tacular finding that the complete destruction of the β-cells
by streptozotocin does not result in hyperglycemia in mice
in which the glucagon receptor has been genetically ab-
lated [51], whereas wild-type mice are severely diabetic
following β-cell ablation, underscores the importance of
glucagon in glucose homeostasis. Because expression of
the glucagon receptor in the liver alone is sufficient to
produce severe diabetes in glucagon receptor-null mice
lacking functional β-cells [51], suppression of glucagon-
induced hepatic glucose output would appear to be a good
target for T2D therapy.
Metformin, widely used to treat T2D (especially in the
obese), has been proposed to lower blood glucose by an-
tagonizing glucagon action [52]. This appears to be me-
diated via reduced cellular metabolism, which leads to
inhibition of adenylyl cyclase and cyclic AMP production,
and so lowers hepatic gluconeogenesis. Other strategies
for reducing glucagon action include reducing glucagon
release from pancreatic α-cells [50] and blocking glucagonstimulation of hepatic glucose output [53]. Indeed, gluca-
gon receptor antagonists improve glycemia in T2D [53],
and glucagon-like peptide 1 (GLP1) mimetics and inhib-
itors of dipeptidyl peptidase 4 (DPP4; the enzyme that
inactivates GLP-1) are thought to improve glucose
homeostasis, at least in part, by reducing plasma gluca-
gon levels [54]. Reduced hepatic glucose output may
also be part of the reason why excellent diabetes control
can be rapidly achieved (prior to substantial weight loss)
by a very low calorie diet [55]. A better understanding
of the mechanisms regulating glucagon secretion and
action, both in health and disease, and of how these
may be targeted therapeutically in T2D is therefore ur-
gently required.
Can β-cell dysfunction in type 2 diabetes be
reversed?
The UK Prospective Diabetes Study Group (UKPDS)
demonstrated that there is an inexorable decline in β-cell
function with time, whether with diet-control, insulin or
sulfonylurea therapies [1]. A key question is what causes
this decline and whether it can be reversed.
Improvement in insulin secretion after intensive insulin
treatment has been reported [56,57], and a very low-calorie
diet can improve insulin action, β-cell function and glucose
homeostasis in T2D patients [55]. Thus, some reversal of
impaired β-cell function in T2D appears possible, at least
in the short term.
Current pharmacological therapies also improve gly-
cemic control in T2D by increasing insulin secretion.
These include the sulfonylurea drugs, which act by closing
KATP channels. Drugs that mimic or amplify the action of
gut hormones - known as incretins - also enhance insulin
secretion. Glucagon-like peptide-1 (GLP-1), for example, is
released from intestinal L-cells in response to the presence
of food in the gut, and like other incretins, it potentiates
insulin secretion at stimulatory glucose concentrations,
but not at low glucose [58]. This makes GLP-1 an at-
tractive therapeutic target, because it enhances insulin
secretion only in response to a meal, when it is needed,
and not during inter-meal intervals when it could in-
crease the risk of hypoglycemia. Thus, GLP-1 mimetics
and DPP4 inhibitors are now widely used. They are
highly effective at boosting insulin secretion and main-
taining glucose homeostasis in T2D patients [54], and
they do not cause the weight gain and hypoglycemia risk
associated with insulin and sulfonylurea therapies [59].
However, questions have been raised over the long-term
safety of incretin-based therapies: in particular, an off-
target effect on ductal cells of the exocrine pancreas
may increase the incidence of pancreatitis, potentially
leading to pancreatic cancer [60,61]. There is debate
about whether the potential risk is justified by the pro-
found benefits of incretin-based medications.
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rapidly restores glucose homeostasis in T2D patients,
prior to the substantial weight loss associated with this
procedure [62]. One explanation for this remarkable find-
ing is that surgery results in an increase in GLP1 secretion
and an associated rise in insulin release [63]. Therefore,
gastric bypass surgery may be a viable surgical therapy for
treating T2D.Where can we expect progress in our understanding
of β-cell failure in type 2 diabetes?
As ever, research on T2D is a vibrant field and much en-
ergy is directed towards understanding the changes in
β-cell function associated with diabetes. The root cause
of defective stimulus-secretion coupling during T2D
remains elusive, and more functional studies using islets
isolated from humans with T2D are clearly needed.
Currently, there is a renewed focus on β-cell dedifferen-
tiation using mouse models, and how this may be pre-
vented or reversed, and on the extent to which other
islet cells can be induced to differentiate into β-cells.
The role of glucagon in T2D is also receiving considerable
attention, and there is an emphasis on efforts towards bet-
ter stratification of disease phenotypes in genetic studies.
Recent therapeutic developments also hint at the possibil-
ity of restoring endogenous β-cell function, although the
long-term stability, safety and efficacy of these approaches
is not yet known. We look forward to the results of all of
these studies.
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